April 25, 2025
Announcement no. 12
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes
Completion of share capital increase
COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) - The Board of Directors of BioPorto A/S ("BioPorto" or the "Company") (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), decided on April 15, 2025, to complete a private placement of 25,000,000 new shares to existing larger shareholders, new professional investors, board members and the management team (company announcement no. 11 of April 15, 2025).
Completion of the issue
BioPorto has now received the full subscription amount and the capital increase of a total nominal amount of DKK 25,000,000 has been registered and completed with the Danish Business Authority.
BioPorto's gross proceeds from the issue will amount to DKK 33,505,000. The new shares correspond to 5.8% of BioPorto's registered share capital prior to the share capital increase and are exempt from the requirement to publish a prospectus.
Admission to trading and official listing
The new shares have the same rights as the existing shares. The new shares carry the right to receive dividend from the time the share capital increase is registered with the Danish Business Authority. The new shares will, as soon as possible be admitted to trading and official listing on Nasdaq Copenhagen A/S under the Company's permanent ISIN-code (DK0011048619).
Share capital and votes
Pursuant to section 32 of the Danish Capital Markets Act, BioPorto's nominal share capital amounts to DKK 454,670,461, consisting of 454,670,461 shares of nominally DKK 1.00 equivalent to 454,670,461 votes. BioPorto's Articles of Association have been updated accordingly and are available on the Company's website.
To receive BioPorto's Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/.
Investor Relations Contacts
Hanne S. Foss, Head of Investor Relations, BioPorto A/S, investor@bioporto.com, C: +45 26368918
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers - tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company's tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company's flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.
